The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET PRE-OPEN: IWG cuts 2021 outlook on continued Covid drag

Mon, 07th Jun 2021 07:44

(Alliance News) - Stocks in London are set for a muted start to the week after Chinese trade data, while strong, undershot expectations.

In early UK company news, office workspace provider IWG cut its full-year earnings outlook on prolonged coronavirus disruption, while Martin Sorrell's S4 Capital lifted its guidance on the back of accelerating trade.

IG says futures indicate the FTSE 100 index of London large-caps to open 7.76 points higher, or 0.1%, at 7,076.80 on Monday. The FTSE 100 closed up 4.69 points, or 0.1%, at 7,069.04 on Friday.

The subdued call comes despite a rally on Wall Street on Friday. The Dow Jones Industrial Average closed up 0.5%, the S&P 500 up 0.9% and the Nasdaq Composite up 1.5%.

"Despite Friday's strong finish in the US, European markets look set to open the week slightly on the back foot after the latest China trade data for May showed that exports slowed more than expected," said Michael Hewson, chief market analyst at CMC Markets.

China's exports rose 28% in May while imports grew at the fastest pace in more than a decade as the global economy powers back from the pandemic crisis, official data showed overnight. While growth was strong, it failed to live up to expectations of a 32% gain.

Demand for China's goods has bounced after economically painful lockdowns last year due to the Covid-19 crisis, and as vaccines are rolled out across much of the world. The figures are also boosted by last year's low base of comparison when the coronavirus was spreading rapidly.

In May, import growth hit its highest rate since January 2011, coming in at 51% on-year, also slightly below expectations of a Bloomberg poll of analysts.

In China, the Shanghai Composite was down 0.1%, while the Hang Seng index in Hong Kong was down 0.5%.

In Tokyo, the Nikkei 225 index closed up 0.3%. The yen was trading lower, with the dollar quoted at JPY109.51 early Monday, up versus JPY109.44 late Friday in London.

The S&P/ASX 200 in Sydney ended down 0.2%.

CMC's Hewson added: "US Treasury Secretary Janet Yellen said that higher interest rates might not be such a bad thing in comments made at the weekend, helping to push US bond yields higher, and take some of the steam out of last weeks end of week rebound in stock markets."

Over the weekend Yellen also hailed an "unprecedented commitment" by the G7 wealthy nations to achieve a global minimum corporate tax rate of at least 15%.

"That global minimum tax would end the race-to-the-bottom in corporate taxation," she said in a statement after the other G7 nations backed US President Joe Biden's plan to get tech giants in particular to pay more.

Following the two-day gathering in London, the G7 said in a final communique that it will "commit to a global minimum tax of at least 15% on a country by country basis". The G7 – comprising Britain, Canada, France, Germany, Italy, Japan and the US – said it hoped to reach a final tax agreement at the July gathering of the expanded G20 finance ministers group.

Facebook even got behind the move despite the social media giant facing the prospect of having to pay more tax – while non-governmental organizations said it did not go far enough.

In early UK company news, IWG guided to full-year earnings "well below" 2020 due to a slower-than-expected recovery.

The office workspace provider said it has continued to see strong recovery in some of its markets since updating on first quarter activity, but the overall improvement across the group has been less than expected due to "prolonged" Covid-19 fallout, including lockdown restrictions and the emergence of new variants.

As such, this will delay IWG's anticipated recovery and, in turn, is expected to have a "significant impact" on its 2021 results, with underlying group earnings before interest, tax, depreciation and amortisation now seen "well below" 2020's level. However, the company said its expectation for a strong recovery in 2022 is unchanged.

IWG said: "In markets where Covid-19 related restrictions are easing such as the US, we have seen positive momentum. Occupancy is improving, enquiries have reached pre-Covid-19 levels, we have an increasing pipeline of corporate customers on network-wide deals and service revenues are starting to improve. These positive trends support the board's view that the prolonged impact of Covid-19 on the group's 2021 results is one of timing."

Grocer Tesco said that it and France's Carrefour have decided not to extend their purchasing alliance beyond the three years agreed back in 2018.

"Over the last three years, Tesco and Carrefour have benefited from a number of joint buying opportunities across food and general merchandise categories, enabling access to new suppliers, new sources and new products. Moving forward, both companies have agreed that they will continue this work independently and focus on their own opportunities, building on the experience and the progress made during the alliance period," said Tesco.

The alliance will run until the end of 2021 and then end.

AstraZeneca said results from the head-to-head Elevate-RR phase three trial of Calquence showed non-inferior progression-free survival and statistically significantly fewer events of atrial fibrillation versus ibrutinib in adults with previously treated chronic lymphocytic leukaemia.

Patients treated with Calquence had a statistically significantly lower incidence of all-grade atrial fibrillation compared with patients treated with ibrutinib, a key secondary endpoint, the pharmaceutical firm highlighted.

Separately, updated results at four years of follow-up from the Elevate-TN phase three trial continued to show a strong progression-free survival benefit for Calquence as combination therapy or as monotherapy in previously untreated patients with chronic lymphocytic leukaemia, the most common type of leukemia in adults.

Germany-focused business park operator Sirius Real Estate reported a jump in full-year profit as it performed well during the pandemic.

Pretax profit surged 48% year-on-year to EUR163.7 million, including EUR103.9 million of gains from property revaluations. Annualised rent roll rose 7.6% to EUR97.2 million, with the company noting the like-for-like increase of 5.2% marked the seventh consecutive year of growth exceeding the 5.0% mark.

Sirius Real Estate's total dividend for the year was 3.80 cents, up 6.4% on the year before.

"The comprehensive governmental response to the pandemic in Germany appears to have succeeded in maintaining employment and limiting the economic damage that many had predicted. Whilst there still remains some uncertainty as the roll out of vaccination programmes in Germany and across Europe continues, the company's performance over the last year gives reason for cautious optimism going forward," said Sirius Real Estate.

Ad agency S4 Capital boosted its guidance after a strong start to 2021.

The firm's executive chair, Martin Sorrell, said ahead of Monday's annual general meeting that trading in the first four months of the year has "accelerated strongly", with revenue up almost 90% versus a rise of 71% for the first quarter. Net revenue was up almost 84% compared with 71% for the first quarter.

"We do not have our May figures as yet, but early indications are that May will be similar to April and that in June, the pipeline continues to be robust," the digital advertising and marketing services company said.

In light of the pick-up in trade during the second quarter so far, S4 has raised its guidance for net revenue growth to 35% from 30% seen previously.

"We are confident that we will be able to deliver sector leading, high double-digit like-for-like revenue and gross profit growth for 2021, along with a strong operating earnings before interest, taxes, depreciation and amortisation margin," said Sorrell.

Over the weekend, Reckitt Benckiser on Saturday announced it has agreed to sell its infant nutrition business in China to Beijing-based investment firm Primavera Capital Group for USD2.2 billion.

The Slough, Berkshire-based consumer health and hygiene products company's disposal will include the manufacturing plants in Nijmegen in the Netherlands and Guangzhou, China, as well as a royalty-free perpetual and exclusive licence of the Mead Johnson and Enfa brands in China. Reckitt will continue to own the Mead Johnson and Enfa family of brands globally.

Sterling was quoted at USD1.4119 early Monday, easing from USD1.4169 at the London equities close on Friday. The euro traded at USD1.2155, down from USD1.2172 late Friday.

Gold was quoted at USD1,883.62 an ounce early Monday, lower than USD1,893.48 on Friday. Brent oil was trading at USD71.37 a barrel, flat on USD71.55 late Friday.

In Monday's economic calendar there are UK Halifax house prices at 0830 BST. At 0930 BST is eurozone investor confidence.

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.